kidney disease
FDA knocks back Mallinckrodt’s kidney drug terlipressin
Phil Taylor
kidney disease, liver disease, Mallinckrodt, regulatory, terlipressin
0 Comment
R&D/ Views & Analysis/ Views and analysis
Renal disease: the big picture
Catherine Longworth
dialysis, kidney disease, renal disease, Sanifit
0 Comment
Sanofi’s venglustat bombs again, but isn’t dead yet
Phil Taylor
kidney disease, nephrology, rare disease, Sanofi, Sanofi Genzyme, venglustat
0 Comment
FDA sets September review date for Calliditas’ rare kidney disease drug
Phil Taylor
autoimmune disease, Calliditas, fda, IGaN, kidney disease, nephrology, rare disease
0 Comment
Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon
Phil Taylor
autoimmune disease, Calliditas, ema, kidney disease, nephrology, rare disease
0 Comment
News/ News/ Sales and Marketing
Pharma poised to cash in on ‘long COVID’ symptoms
Richard Staines
COVID-19, heart failure, idiopathic pulmonary fibrosis, infectious diseases, kidney disease, Long COVID, mental health
0 Comment
R&D/ Views & Analysis/ Views and analysis
Ardelyx’s ambition to revolutionise kidney treatment
Catherine Longworth
Ardelyx, COVID-19, hyperphosphatemia, kidney disease, kidneys, Tempanor
0 Comment
Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel
Phil Taylor
fda, kidney disease, liver disease, Mallinckrodt, rare disease, terlipressin
0 Comment